|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
06826 HAOHAI BIOTEC
Nominal 
16.730 +0.229 (+1.388%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 1,165,842 | -9.809% | 2,446,306 | 2,679,667 | 2,634,910 | 2,103,438 |
| Cost of Sales | (406,254) | 5.149% | (734,729) | (810,879) | (781,401) | (656,515) |
| Gross Profit | 759,588 | -16.186% | 1,711,577 | 1,868,788 | 1,853,509 | 1,446,923 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 75 | -- | (4,620) | 2,229 | 1,973 | (15,516) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (328) | 429.032% | 10 | 986 | 456 | 3,505 | |
| Profit / (Loss) before Taxation | 132,583 | -43.733% | 239,246 | 466,145 | 508,260 | 235,726 | |
| Taxation | (22,063) | -35.042% | (30,924) | (89,902) | (95,991) | (45,395) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 2,107 | -77.585% | 42,687 | 44,204 | 3,852 | (9,861) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 112,627 | -46.639% | 251,009 | 420,447 | 416,121 | 180,470 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (18,949) | -30.823% | (57,998) | (55,901) | (70,436) | (80,280) |
| Depreciation & Amortisation | 114,005 | 10.321% | 206,759 | 205,226 | 197,855 | 204,217 |
| Directors' Emoluments | -- | -- | -- | 10,467 | 9,007 | 9,714 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 49.000 | -46.154% | 108.000 | 180.000 | 174.286 | 74.286 |
| DPS (cts) | 25.000 | -- | 100.000 | 100.000 | 71.429 | 28.571 |
| Dividend Payout Ratio (%) | 51.020% | -- | 92.593% | 55.556% | 40.984% | 38.462% |
| Cash flow per share ($) | -- | -- | 2.118 | 2.782 | 2.657 | 1.333 |
| NBV per share ($) | 23.571 | -- | 23.915 | 23.908 | 23.535 | 22.621076 |
| Remarks: | Real time quote last updated: 04/09/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 112,627 |
| %Change | -46.639% |
| EPS / (LPS) | RMB 0.490 |
| NBV Per Share (¥) | RMB 23.571 |